Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × rrCLL × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 140 Parkinson Disease 4, Autosomal Dominant Lewy Body 117 Melanoma 81 Squamous Cell Carcinoma of Head and Neck 53 Neoplasms 42 Breast Neoplasms 40 Triple Negative Breast Neoplasms 37 Stomach Neoplasms 36 Colorectal Neoplasms 36 Neoplasm Metastasis 35 Carcinoma, Renal Cell 34 Lung Neoplasms 30 Ovarian Neoplasms 29 Urinary Bladder Neoplasms 28 Head and Neck Neoplasms 28 Carcinoma, Transitional Cell 26 Carcinoma, Hepatocellular 25 Pancreatic Neoplasms 22 Esophageal Neoplasms 20 Endometrial Neoplasms 16 Prostatic Neoplasms 15 Multiple Myeloma 15 Fallopian Tube Neoplasms 14 Sarcoma 13 Recurrence 13 Carcinoma 13 Small Cell Lung Carcinoma 12 Lymphoma, Large B-Cell, Diffuse 12 Lymphoma, Follicular 12 Leukemia, Myeloid, Acute 11

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡